FDA approval in 1987.
Relevant studies: GUSTO trial, 1993 (5).
Dose, accelerated scheme (6):
FDA approval for <3 hours after symptom onset in 1996 (15). Universally accepted use for <4.5 hours (3, 7).
Relevant studies: NINDS trial, 1995 (8). ECASS III trial, 2008 (9).
FDA approval in 2002 for high risk PE, but also for “PE obstructing blood flow to a lobe or multiple lung segments” which is controversial if it is not causing hemodynamic deterioration. Usage in intermediate-high risk PE has been questioned, studied schemes do not support fibrinolysis as a standard intervention; if considered, always decide under the supervision of a specialist, in this scenario Pulmonary Embolism Response Teams (PERTs) are recommended (2, 11, 12). For cardiac arrest it can be used in selected cases, with very limited available data (10).
Recommended review: European Society of Cardiology PE Guidelines, 2019 (2).
Dose (6, 2, 10)